ThromboGenics has announced that the results from its 2 Year OASIS Phase IIIb study with Jetrea (ocriplasmin) in patients with...
Astellas Pharma Inc. announced positive topline results from the Phase IIIb DAYLIGHT clinical trial for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) due to menopause . VMS, characterized by hot flashes and/or night sweats, are common symptoms of menopause.
Eli Lilly and Company announced Taltz (ixekizumab) met the primary and all major secondary endpoints in the Phase IIIb/IV SPIRIT-H2H...
Novartis has announced full results from the Phase IIIb LIBERTY trial of Aimovig (erenumab, AMG 334) in episodic migraine patients...
Takeda announced results from its phase IIIb/IV PROPEL trial for Adynovate (recombinant factor VIII), a PROspective, randomized, multi-center study comparing...
AstraZeneca announced top-line results from the AERISTO Phase IIIb trial for Bevespi Aerosphere (glycopyrronium/formoterol fumarate) in patients with moderate to...
AstraZeneca presented positive results from the Phase IIIb DIALIZE trial which investigated the efficacy and safety of Lokelma (sodium zirconium...
Novo Nordisk announced new phase IIIb trial (DUAL VII) results with Xultophy (IDegLira). Xultophy is a once-daily, single injection fixed...
AstraZeneca announced top-line results from the Phase IIIb/IV EXSCEL (EXenatide Study of Cardiovascular Event Lowering) trial. The trial compared the...
Daiichi Sankyo announced results from phase IIIb ELIMINATE-AF, a prospective, randomised, open label, blinded endpoint evaluation (PROBE) design study assessing...